Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Medicare Formulary Reviews Include 14 Checkpoints

Executive Summary

The Centers for Medicare & Medicaid Services has a 14-point checklist it is using in the review of Medicare Part D drug formularies

You may also be interested in...

Part D Sponsors Will Develop Plans To Target Dual-Eligibles, Panel Says

Medicare Part D plan sponsors will develop specific prescription drug plans to target dual-eligible beneficiaries, panelists said during a Kaiser Family Foundation workshop on Medicare formularies March 14 in Washington, D.C

Medicare Formularies Should Contain “Majority” Of Drugs In Six Classes

Medicare drug plan formularies will be expected to cover the "majority" of products in six specific drug classes, the Centers for Medicare & Medicaid Services final formulary review guidelines state

USP Final Formulary Guide Adds PPI Class, But Has Few Other Changes

Proton pump inhibitors may be the only commercially significant group of drugs to gain "pharmacologic class" status in the revisions to U.S. Pharmacopeia's model guidelines for Medicare drug plans





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts